Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia

Oncotarget

Volumn 7, Issue 16, 2016, Pages 21713-21727

  Kamga, Paul Takam ^a   Bassi, Giulio ^a   Cassaro, Adriana ^a   Midolo, Martina ^a   Di Trapani, Mariano ^a   Gatti, Alessandro ^a   Carusone, Roberta ^a   Resci, Federica ^a   Perbellini, Omar ^a   Gottardi, Michele ^b   Bonifacio, Massimiliano ^a   Kamdje, Armel Hervé Nwabo ^c   Ambrosetti, Achille ^a   Krampera, Mauro ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b CA FONCELLO HOSPITAL   (Italy)

^c UNIVERSITY OF NGAOUNDERE   (Cameroon)

Author keywords

AML; Chemoresistance; MSC; Notch

Indexed keywords

IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JAGGED1; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PROTEIN KINASE B; STAT3 PROTEIN; TRANSCRIPTION FACTOR HES 1; BENZYLOXYCARBONYL-LEUCYL-LEUCYL-NORLEUCINAL; OLIGOPEPTIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW STROMA CELL; CANCER RESISTANCE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PROTEIN EXPRESSION; PROTEIN FUNCTION; ACUTE DISEASE; ADULT; AGED; ANTAGONISTS AND INHIBITORS; BONE MARROW CELL; CELL CULTURE; CELL DIFFERENTIATION; COCULTURE; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; HL-60 CELL LINE; K-562 CELL LINE; MALE; MESENCHYMAL STROMA CELL; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; TUMOR CELL LINE; U-937 CELL LINE;

ACUTE DISEASE; ADULT; AGED; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; DRUG RESISTANCE, NEOPLASM; FEMALE; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID; MALE; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OLIGOPEPTIDES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; U937 CELLS;

EID: 84965082789     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7964     Document Type: Article

References (35)

1. Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011; 2(2):95-107. doi:10.1177/1947601911408076
2. Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L and Bhatia R. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood. 2013; 121:1824-1838.
3. Ito S, Barrett AJ, Dutra A, Pak E, Miner S, Keyvanfar K, Hensel NF, Rezvani K, Muranski P, Liu P, Melenhorst JJ and Larochelle A. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells. Stem Cell Res. 2015; 14:95-104.
4. Nwabo Kamdje AH, Mosna F, Bifari F, Lisi V, Bassi G, Malpeli G, Ricciardi M, Perbellini O, Scupoli MT, Pizzolo G and Krampera M. Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. Blood. 2011; 118:380-389.
5. Nwabo Kamdje AH, Bassi G, Pacelli L, Malpeli G, Amati E, Nichele I, Pizzolo G and Krampera M. Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. Blood Cancer J. 2012; 2:e73.
6. South AP, Cho RJ and Aster JC. The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol. 2012; 23:458-464.
7. Grabher C, von Boehmer H and Look AT. Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2006; 6:347-359.
8. Aster JC. Deregulated NOTCH signaling in acute T-cell lymphoblastic leukemia/lymphoma: new insights, questions, and opportunities. Int J Hematol. 2005; 82:295-301.
9. Rosati E, Sabatini R, De Falco F, Del Papa B, Falzetti F, Di Ianni M, Cavalli L, Fettucciari K, Bartoli A, Screpanti I and Marconi P. gamma-Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down-regulation. Int J Cancer. 2013; 132:1940-1953.
10. Rosati E, Sabatini R, Rampino G, Tabilio A, Di Ianni M, Fettucciari K, Bartoli A, Coaccioli S, Screpanti I and Marconi P. Constitutively activated Notch signaling is involved in survival and apoptosis resistance of B-CLL cells. Blood. 2009; 113:856-865.
11. Lobry C, Ntziachristos P, Ndiaye-Lobry D, Oh P, Cimmino L, Zhu N, Araldi E, Hu W, Freund J, Abdel-Wahab O, Ibrahim S, Skokos D, Armstrong SA, Levine RL, Park CY and Aifantis I. Notch pathway activation targets AMLinitiating cell homeostasis and differentiation. J Exp Med. 2013; 210:301-319.
12. Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM, Akers LJ, Hammitt RA, McMurray JS, Kornblau SM, Melnick AM, Figueroa ME and Zweidler-McKay PA. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med. 2013; 210:321-337.
13. Tohda S, Kogoshi H, Murakami N, Sakano S and Nara N. Diverse effects of the Notch ligands Jagged1 and Delta1 on the growth and differentiation of primary acute myeloblastic leukemia cells. Exp Hematol. 2005; 33:558-563.
14. Xu X, Zhao Y, Xu M, Dai Q, Meng W, Yang J and Qin R. Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia. Med Oncol. 2011; 28 Suppl 1:S483-489.
15. Sliwa T, Awsa S, Vesely M, Rokitte D, Grossschmidt P, Jilch R, Ulrich W and Geissler K. Hyperexpression of NOTCH-1 is found in immature acute myeloid leukemia. Int J Clin Exp Pathol. 2014; 7:882-889.
16. Grieselhuber NR, Klco JM, Verdoni AM, Lamprecht T, Sarkaria SM, Wartman LD and Ley TJ. Notch signaling in acute promyelocytic leukemia. Leukemia. 2013; 27:1548-1557.
17. Tohda S, Murata-Ohsawa M, Sakano S and Nara N. Notch ligands, Delta-1 and Delta-4 suppress the self-renewal capacity and long-term growth of two myeloblastic leukemia cell lines. Int J Oncol. 2003; 22:1073-1079.
18. Murata-Ohsawa M, Tohda S and Nara N. Cellular analysis of growth suppression induced by the Notch ligands, Delta-1 and Jagged-1 in two myeloid leukemia cell lines. Int J Mol Med. 2004; 14:223-226.
19. Scott AM, Wolchok JD and Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012; 12:278-287.
20. Ruvolo PP, Qiu Y, Coombes KR, Zhang N, Neeley ES, Ruvolo VR, Hail N, Jr., Borthakur G, Konopleva M, AndreeffM and Kornblau SM. Phosphorylation of GSK3alpha/beta correlates with activation of AKT and is prognostic for poor overall survival in acute myeloid leukemia patients. BBA Clin. 2015; 4:59-68.
21. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB and Tweardy DJ. Stat3 signaling in acute myeloid leukemia: liganddependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood. 2011; 117:5701-5709.
22. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, Dageville C, Sirvent A, Hummelsberger M, Berard E, Dreano M, Sirvent N and Peyron JF. Targeting NFkappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood. 2005; 105:804-811.
23. Tchou J and Conejo-Garcia J. Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Adv Pharmacol. 2012; 65:45-61.
24. Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, Hair A, Holyoake TL, Huettner C and Bhatia R. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell. 2012; 21:577-592.
25. Seke Etet PF, Vecchio L and Nwabo Kamdje AH. Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways? Cell Signal. 2012; 24:1433-1443.
26. Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N, Khiabanian H, Lee A, Murty VV, Friedman R, Brum A, Park D, Galili N, et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature. 2014; 506:240-244.
27. Chiaramonte R, Basile A, Tassi E, Calzavara E, Cecchinato V, Rossi V, Biondi A and Comi P. A wide role for NOTCH1 signaling in acute leukemia. Cancer Lett. 2005; 219:113-120.
28. Kato T, Sakata-Yanagimoto M, Nishikii H, Ueno M, Miyake Y, Yokoyama Y, Asabe Y, Kamada Y, Muto H, Obara N, Suzukawa K, Hasegawa Y, Kitabayashi I, et al. Hes1 suppresses acute myeloid leukemia development through FLT3 repression. Leukemia. 2015; 29:576-585.
29. Yuan Y, Lu X, Chen X, Shao H and Huang S. Jagged1 contributes to the drug resistance of Jurkat cells in contact with human umbilical cord-derived mesenchymal stem cells. Oncol Lett. 2013; 6:1000-1006.
30. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS and Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008; 111:2220-2229.
31. Pan R, Ruvolo VR, Wei J, Konopleva M, Reed JC, Pellecchia M, AndreeffM and Ruvolo PP. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Blood. 2015; 126:363-372.
32. Darnowski JW, Goulette FA, Guan YJ, Chatterjee D, Yang ZF, Cousens LP and Chin YE. Stat3 cleavage by caspases: impact on full-length Stat3 expression, fragment formation, and transcriptional activity. J Biol Chem. 2006; 281:17707-17717.
33. Luo HR, Hattori H, Hossain MA, Hester L, Huang Y, Lee-Kwon W, Donowitz M, Nagata E and Snyder SH. Akt as a mediator of cell death. Proc Natl Acad Sci U S A. 2003; 100:11712-11717.
34. Kang KH, Lee KH, Kim MY and Choi KH. Caspase-3-mediated cleavage of the NF-kappa B subunit p65 at the NH2 terminus potentiates naphthoquinone analog-induced apoptosis. J Biol Chem. 2001; 276:24638-24644.
35. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM, Benzaquen D, Laurent G, Huguet F and Payrastre B. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005; 105:2527-2534.